Human Genetics and Genetic Diseases

Biography

Biography: Komar Aleksandra

Abstract

Introduction: The anti-inflammatory cytokine interleukin-10 (IL10) may play a protective role in type 2 diabetes (T2D). The Wnt5a signaling pathway regulates the production of a wide range of cytokines in stellate cells of the liver, so we suggest a relationship between the expression of the WNT5a gene in the liver and the content of IL-10 in the circulation in obese patients with and without T2D.

Methodology & Theoretical Orientation: Serum glucose levels were determined on a biochemical analyzer; the concentration of IL10 in blood plasma - by flow fluorimetry; WNT5a gene expression level - by PCR; quantitative content of protein WNT5A – by Western Blotting.

Findings: Expression of the gene Wnt5a in the group of obese patients without diabetes increased by 1.7 times (p<0.05); the group of obese patients with diabetes increased by 1.47 times (p<0.05). Liver protein Wnt5a levels consistent with gene expression Wnt5a. Plasma blood IL10 levels in patients with type 2 diabetes were lower than in patients without type 2 diabetes [1]. Pereira C. et al.  was found the inhibitory effect of Wnt5a overexpression on the anti-inflammatory cytokine IL10 in a culture of isolated macrophages and a decreased in the release of pro-inflammatory cytokines [1]. While a low IL10 concentration in blood plasma can contribute to the development of chronic inflammation in patients with T2D [2]. The level of IL10 negatively correlated with the level of expression of the WNT5a gene in the liver in patients with type 2 diabetes (r=-0,548, Ñ€<0.05). High expression of WNT5A in the liver was associated with a high IL10 plasma level in patients with obesity without type 2 diabetes and a low IL10 plasma level in patients with obesity with type 2 diabetes.

Conclusion & Significance: Thus, a high level of WNT5a gene expression can be associated with the protective effect of IL 10 in obese patients without T2D.